Comparing new chemo plus immunotherapy with standard chemo for HER2-positive breast cancer
Part of Cancer clinical trials.
This trial compares two different chemotherapy combinations (one with a newer type of paclitaxel called polymeric micelles, plus an immunotherapy drug called adebelimab) against a standard taxane plus HP regimen, as first-line treatment for advanced HER2-positive breast cancer. The goal is to see if the new combination works better at controlling the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your breast cancer must be HER2-positive (a protein that helps cancer grow).
- Your cancer must have a protein called PD-L1 (CPS score of 1 or more).
- You must not have had chemotherapy or HER2-targeted therapy for advanced or metastatic breast cancer before, though treatment before it spread is okay if it finished more than 6 months ago.
- You need to be in good overall health, able to do daily activities, and have normal enough heart, liver, kidney, and blood counts.
- You must have at least one tumor that can be measured on a CT or MRI scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial tests a new combination of drugs for people with HER2-positive early breast cancer whose tumors did not respond well to the first round of standard targeted therapy plus chemo. The goal is to see if switching to trastuzumab-rezetecan plus pertuzumab or a different chemo combo (nab-paclitaxel, carboplatin, trastuzumab, and pyrotinib) can shrink the tumor before surgery.
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial tests a treatment for HER2-positive breast cancer given without intravenous (IV) therapy - likely as injections under the skin. It aims to see if this approach is effective before surgery.
Hear when a new Advanced HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.